Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Colorcon
Dow
AstraZeneca
Harvard Business School

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Litigation Details for Abbott Laboratories v. Hospira Inc. (D. Del. 2012)

See Plans and Pricing

« Back to Dashboard

Abbott Laboratories v. Hospira Inc. (D. Del. 2012)

Docket   Start Trial Date Filed 2012-02-27
Court District Court, D. Delaware Date Terminated 2014-12-10
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties ABBOTT LABORATORIES; HOSPIRA INC.; WISCONSIN ALUMNI RESEARCH FOUNDATION
Patents 5,246,925; 5,587,497; 5,597,815; 6,136,799; 6,361,758
Attorneys Jeremy A. Tigan; Jeremy Alexander Tigan; Mary B. Graham; Melanie K. Sharp; Monte Terrell Squire; Richard D. Kirk
Link to Docket External link to docket
Small Molecule Drugs cited in Abbott Laboratories v. Hospira Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Abbott Laboratories v. Hospira Inc. (D. Del. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-02-27 1 additional patent listed in the Orange Book as covering paricalcitol, U.S. Patent No. 5,587,497 (“the ’497…action for infringement of U.S. Patent No. 5,597,815 (“the ’815 patent”). This action arises out of Hospira…civil action for patent infringement and declaratory judgment arising under the patent laws of the United…of the ’815 patent is attached hereto as Exhibit A. 9. The ’815 patent expires on…815 patent claims an approved use of paricalcitol as set forth in the FDA’s Orange Book, Patent Use External link to document
2012-03-19 5 belief, U.S. Patent Nos. 5,246,925 and 5,587,497 (“the ’925 patent” and “the ’497 patent) were listed …that U.S. Patent No. 6,136,799 (“the ’799 patent”) and U.S. Patent No. 6,361,758 (“the ’758 patent”) are …January 28, 1997, U.S. Patent No. 5,597,815 (“the ’815 patent”) issued. The ’81 5 patent is entitled “Prevention…action for infringement of U.S. Patent No. 5,597,815 (“the ’815 patent”) arising out of Hospira’s NeW …action for patent infringement and declaratory judgment arising under the United States Patent Laws, 35 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Baxter
Merck
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.